1 The Risk of Mpox (Monkeypox) Importation and Subsequent Outbreak Potential in

2 Mainland China: A Retrospective Statistical Modelling Study

3 Xiaowei Deng¹[†], Yuyang Tian¹[†], Junyi Zou¹, Juan Yang¹, Kaiyuan Sun^{2*}[§], Hongjie Yu^{1*}[§] 4 5 ¹School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of 6 Education. Shanghai, China.²Division of International Epidemiology and Population Studies. 7 Fogarty International Center, National Institutes of Health, Bethesda, MD, USA. 8 9 ^{*}Address correspondence to: Hongjie Yu; yhj@fudan.edu.cn and Kaiyuan Sun; 10 kaiyuan.sun@nih.gov 11 12 [†]These authors contributed equally to this work. 13 §These authors contributed equally to this work. 14 15 Abstract 16 The 2022 mpox outbreak has spread rapidly across multiple countries in the non-endemic region, 17 mainly among men who have sex with men (MSM), while China only has limited recorded 18 importation and no local outbreak. We constructed probabilistic models to simulate the risk of 19 mpox importation in mainland China, with the help of reported monkeypox cases during this 20 multi-country outbreak and the international air-travel data. And we further evaluated the mpox 21 22 outbreak potential given that undetected mpox infections were introduced into men who have sex with men, considering different transmissibility, population immunity and population activity. We 23 found that the reduced international air-travel volume and stringent border entry policy decreased 24 about 94% and 69% mpox importations respectively. Once a mpox case is introduced into active 25 MSM population with almost no population immunity, the risk of triggering local transmission is 26 estimated at 42%, and would rise to >95% with over six cases. Our study demonstrates the key 27 role of the reduced international air-travel volume and stringent border entry policy during the 28 29 COVID-19 pandemic on reducing mpox importations, and the subsequent risk of triggering local

30 outbreaks among MSM.

31

32 Introduction

Since the first human infection was detected in Central Africa in 1970(1), the monkeypox virus 33 has been recognized as a viral zoonosis with endemic regions primarily concentrated in west and 34 central African countries(2, 3). The monkeypox virus, a member of the Orthopoxvirus genus in 35 the Poxviridae family, is closely related to the widely known variola virus (which causes 36 smallpox)(4). In the last two decades, the global incidence of monkeypox cases (here after, 37 monkeypox is denoted as mpox according to WHO reference) has been on the rise in endemic 38 regions, with an increase in the median age among confirmed and probable mpox cases over 39 40 time(5). Before the 2022 multi-country mpox outbreak, imported mpox infections in humans have 41 been reported in the USA(6-9), UK(10), Israel(11), and Singapore(12).

42

43 After the confirmation of a mpox case in England on May 7, 2022, the outbreak has rapidly expanded spatially to other countries in Europe, the Americas, and Western Pacific 44 region(13). It is the first time that mpox cases have been reported in both endemic and non-45 endemic regions with broad geographical coverage. This multi-country mpox outbreak also 46 reveals different epidemiological and clinical characters from previous outbreaks(7, 14-18) (Table 47 48 S1). In particular, sustained human-to-human transmission has been observed, involving 49 predominately men who have sex with men (MSM)(19), which made mpox as a sexually transmitted disease (STD)(20). On July 23, 2022, the WHO declared the multi-country outbreak 50 51 of mpox as a Public Health Emergency of International Concern (PHEIC) due to its unprecedent rapid spread in the non-endemic regions and disparate global dissemination(21, 22), and since 52 May 11, 2023, the WHO cancel the PHEIC declaration. Recently, countries/regions in East Asia 53 54 has started experiencing local mpox outbreaks that were not seen during the height of mpox outbreak in 2022(23). As of June 15, 2023, 181 confirmed cases have reported by Japan and 102 55 cases by the Republic of Korea as of June 5(24, 25). Taiwan province reported over 50 local 56 57 mpox cases in May 2023. It is crucial to evaluate the mpox outbreak potential in mainland China, due to its large pool of susceptible population at risk of mpox and the fundamental change in the 58 59 geographical range of mpox circulation.

60

In this study, we used mathematical models to evaluate: 1) the importation risk by international air travel from countries with ongoing outbreaks; 2) the effectiveness of two sets of border screening strategies considering mainland China's pre- and peri-pandemic (hypothetical) border entry and quarantine policies; 3) the risk of undetected mpox importations to trigger a local outbreak in mainland China across a range of plausible mpox transmissibility and contact patterns among the MSM community.

6768 **Results**

According to the WHO situation report(*26*), as of June 13, 2023, a total of 87,979 confirmed mpox cases were reported among 111 countries and regions, with the majority of cases reported in the American (59,449) and European (25,910) regions, accounting for 67.6% and 29.5% of the global cases (Fig.1).

73 According to the air-travel data from OAG(27), we found the monthly number of arrivals 74 in China was on average 5.69 million during 2017–2019. However, the volume drastically 75 76 decreased to 0.6 million starting in January 2020, approximately one-tenth of the pre-pandemic (2017–2019) air-travel volume (Fig.2a, inset). Assuming a hypothetical scenario that the year 77 2022 has the same air-travel volume as in 2019 (pre-pandemic), we estimated that the expected 78 79 number of mainland China's mpox importations would have risen above one on June 2, 2022 and reached 36 (95% CI: 27–50) on September 11, 2022. In contrast, according to the actual 80 international air travel volume during 2022 (peri-pandemic), we estimated that the expected 81

82 cumulative importations would only reach two (95% CI: 0–5) by September 11, 2022. In Fig.2b, we presented mainland China's top 12 source countries for mpox importations based on the travel 83 volume of year 2019 and 2022, respectively. Under the air-travel volume of 2019, mainland 84 China would expect (on average) more than one mpox infection importation from epidemic 85 countries including the United States (16, 95% CI: 8–23), the United Kingdom (7, 95% CI: 3–12), 86 Spain (4, 95% CI: 1–8), France (4, 95% CI: 0–8), Canada (2, 95% CI: 0–5), Germany (1, 95% CI: 87 0-4) and Netherlands (1, 95% CI: 0-3). In contrast, under the air-travel volume of 2022, we 88 estimated that no single source country would contribute to more than one mpox importation to 89 mainland China, with the highest-ranking country (the United States) contributing to about one 90 91 mpox importation (95% CI: 0-3).

We first examined the effectiveness of a mpox border screening policy (measured as the 93 probability of mpox infection detection among all mpox importations) under mainland China's 94 pandemic quarantine policy for international travelers (Scenario 1). Specifically, we found that 95 under Scenario 1, the effectiveness of border screening against mpox is insensitive to the self-96 97 reporting rate of a mpox epidemiological links, as all international travelers were required to quarantine due to existing pandemic policies. On the other hand, the detection rate of mpox 98 99 importations increases with the quarantine duration (Fig.3a). Mainland China's pandemic policy requiring a quarantine duration of 10 days (policy as of June 28, 2022(28)) would lead to high 100 101 effectiveness of mpox screening with a mpox detection rate reaching >80% based on our model's estimate, irrespective of the self-reporting rate of epidemiological links. However, universal 102 border entry quarantine as a stand-alone policy for mpox, in the absence of pandemic-related 103 policy, is impractical and unwarranted due to mpox's much slower spread compared to COVID-104 19 and the lack of evidence of pre-symptomatic transmission(29). We thus considered a scenario 105 of a border screening policy similar to the contact tracing guidance by the European Center for 106 Disease Prevention and Control (ECDC)(29). In this scenario, both the self-reporting rate of 107 epidemiological links and the duration of the medical observation influence the screening 108 effectiveness: the proportion of imported mpox infections who self-report an epidemiological 109 links sets the upper bound of the mpox border screening effectiveness, as infected individuals 110 who do not report/are unaware of mpox exposure would not undergo medical observation and 111 thus could not be promptly detected (Fig.3b). Among exposed individuals undergoing medical 112 113 observation, increasing the duration of medical observation would increase the detection rate of border screening but the increase would start plateauing with only marginal benefit once the 114 duration reached beyond 10 days. In Fig.3c, we compared the overall effectiveness of Scenario 1 115 against Scenario 2 across a range of quarantine/medical observation durations, conditional on the 116 same proportion of self-reporting epidemiological link (50%). We found that the more stringent 117 Scenario 1 always outperforms Scenario 2 across different quarantine/medical observation 118 durations. At the quarantine/medical observation duration of 10 days, Scenario 1 on average 119 detects 83.3% of imported mpox cases while Scenario 2 could only detect 46.3%. Longer 120 quarantine/medical observation duration does not significantly improve the border screening 121 effectiveness for either of the two scenarios. 122

123

92

Next, we used a mathematical model to evaluate the potential of undetected mpox 124 infections triggering a local mpox outbreak. The outbreak potential of an undetected mpox 125 importation is influenced by the overall transmissibility of the mpox virus (measured as the basic 126 reproduction number R_0) and the transmission heterogeneity (measured as the overdispersion 127 parameter k, Supplement, section 8)(30). In Fig.4a, we demonstrated the outbreak probability of a 128 single undetected mpox infection in the high-risk population as a function of R_0 and k: both the 129 130 increasing of R_0 (increasing transmissibility) and k (decreasing transmission heterogeneity) would increase the outbreak probability. Considering the recent estimation of $R_0=1.8$ for mpox 131

outbreaks in several European countries, the outbreak probability caused by one undetected mpox case was estimated at 42.1% if the overdispersion parameter k was equal to 0.88, based on sexual contact network among MSM in mainland China(31, 32). The outbreak probability drastically goes up with the number of undetected mpox importations, reaching to above 95% with six or more importations. When taking into account of emergency vaccination, the reproduction number is reduced to 1.46 and the outbreak probability accordingly reduces to 29.4% minimum, which is

- 138 70% of the situation with $R_0=1.8$.
- 139

140 Discussion

Since the global eradication of smallpox in the 1980s and subsequent halt of the smallpox 141 vaccination program, it has been suggested that the mpox virus could emerge as the next 142 Orthopoxvirus of epidemic potential in humans, taking up the ecological niche vacated by 143 smallpox in the human population (33). In recent years, increasing incidence and shifting 144 145 demographics towards older populations and males in the endemic region were warning signs of declining of mpox population immunity due to the cessation of smallpox vaccination in the 1980s 146 and population turnover. Following the first confirmed mpox case reported by the United 147 Kingdom in early May 2022, the multi-country mpox outbreak had infected about 86,000 148 individuals in non-endemic regions as of June 13, 2023, with countries in Europe and the 149 Americas being impacted most heavily. After confirming mpox's local transmission, the UK and 150 other European countries subsequently adopted contact tracing and case isolation to control their 151 outbreaks(34, 35). Following the PHEIC declaration of the outbreak by the WHO, the US 152 government declared a public health emergency for the local mpox outbreak and adopted 153 measures (case identification, contact tracing, vaccination) to suppress local transmission. When 154 faced with the importation risk of mpox, only a few countries have strengthened their border 155 screening to prevent case importation(36-41). 156

157

On September 16, 2022, mainland China recorded its first imported mpox case in 158 Chongqing. The case had a travel history to Germany and Spain(42) and remained the only 159 observed mpox importation as of June 5, 2023. This observed low risk of mpox importation is in 160 line with our model's projections based on 2022 air-travel volume. By examining the OAG's data 161 through October 2022, mainland China's air travel has yet to show significant recovery from that 162 of 2022 (Fig.2a) due to the stringent border entry policy that is still in place. Furthermore, as a 163 byproduct of the universal quarantine policy for border entry due to the pandemic, our analysis 164 suggests high border screening effectiveness for mpox if medical observation for mpox were 165 implemented during the mandatory quarantine. Collectively, the impact of pandemic on air-travel 166 reduction and a stringent quarantine policy have led to a low risk of mpox importation in 167 mainland China from the current multi-country mpox outbreak. However, under conditions where 168 air-travel volume is able to rebound to pre-pandemic levels, we estimate that the importation risk 169 is substantially higher, reaching 36 (95% CI: 25-47) mpox importations under the current 170 outbreak (Fig.2a). 171

172 A distinctive feature of the 2022 mpox outbreak is that it affects predominantly the 173 population in the MSM community with sustained human-to-human transmission outside the 174 endemic region(13). Modeling analysis of the UK's sexual contact network of the MSM 175 community suggested the heavy-tailed nature of network topology could result in the basic 176 reproduction number of mpox larger than the epidemic threshold of one among the group of 177 individuals who have disproportionately large numbers of partners (43). We have looked at the 178 distribution of sexual partners among MSM in China in 2010 based on the study by Zhang et. 179 al.(31, 32) (Fig.S3); it is highly heterogeneous, with 4.9% of individuals having more than 10 180 sexual partners over a period of one year. Thus, it is plausible to expect that once mpox infection 181

is introduced into the MSM community in mainland China, the mpox virus could sustain human-182 to-human transmission and cause substantial disease burden in the high-risk population. 183 Assuming the mpox's basic reproduction number in mainland China is similar to that in Europe 184 and the United States (44), we estimate that the probability of triggering a local mpox outbreak is 185 substantial and rapidly goes up with the number of mpox introductions (Fig.4). A recent study 186 suggests that the size of the MSM community in mainland China is approximately eight 187 million(45), roughly twice the size of that in the US(46). With the changing epidemiology and 188 population immunity of mpox as well as the geographical expansion to non-endemic regions, 189 mpox has emerged as a public health threat for mainland China's MSM community in the 190 191 foreseeable future.

193 Although the global mpox epidemic trend has been on the decline since August, 2022, and the WHO declared that the mpox epidemic no longer constituted a PHEIC, mpox is still 194 circulating with low intensity in non-endemic countries/regions recently(22). Several Asian 195 countries including Japan, Thailand, etc. have reported imported and local mpox cases since May, 196 2023(23, 47). Taiwan Province reported over 50 local mpox cases in May, 2023. From June to 197 July, 2023, 23 provinces in mainland China reported 597 confirmed mpox cases, suggesting likely 198 wide-spread mpox local outbreaks in mainland China. This is in agreement with our modeling 199 assessment of high mpox outbreak probability in mainland China, conditional on introduction of 200 201 travel-related mpox cases (Fig.2). We explored the correlation between the confirmed mpox cases and active MSM population size at the province level estimated by Hu et al(45), if we remove 202 Beijing and Guangdong province (both are major international air traffic hubs for mainland 203 China) presented as outliers (Fig.S4). We further performed a regression model including both 204 mpox cases active MSM population size and air-travel volume as covariate (with interaction), 205 without removing Bejing and Guangdong (Supplement, section 10). The result of the regression 206 showed high coefficient of determination ($R^2 = 0.845$), indicating that both the active MSM 207 population size and air-travel volume contribute to explaining mpox cases number. 208

209

192

Our study has several limitations. First, we assumed that the air-travel behavior of the 210 population in the MSM community is the same as that of the general population, which may not 211 be true. Second, we assumed there is no under-reporting of mpox infections, which may lead to an 212 underestimation of the importation risk in mainland China. However, considering the high 213 symptomatic rate of mpox infection as well as distinct symptom presentations including fever and 214 rash, we expect our estimation and our conclusion remain robust. Lastly, data on MSM sexual 215 contact networks are limited in mainland China. In particular our MSM sexual contact network is 216 based on data pre-pandemic (2010), and during the pandemic, the sexual behavioral could have 217 changed substantially. Better characterization of the behavioral aspect of the high-risk population 218 could further improve our evaluation of mpox outbreak potential and define effective preventive 219 220 and mitigation public health policies against mpox.

221

228

Using pre- and peri-pandemic air-travel data and spatiotemporally resolved mpox case reporting, our study demonstrates that the reduced international air-travel volume and stringent border entry policy during the COVID-19 pandemic reduced mpox importations prominently. However, the risk could be substantially higher with the recovery of air-travel volume to prepandemic level. Mpox could emerged as a public health threat for mainland China given its large MSM community.

229 Materials and Methods

230 Simulating the international dissemination of the 2022 multi-country mpox outbreak and

231 evaluating mainland China's importation risk.

To quantify the international importation risk of mpox from a source location *i* (regions with 232 ongoing mpox transmission) to a destination location *j*, we need to know the outbreak size in the 233 source location i and the connectivity between the origin (location i) and destination (location i) 234 by air-travel. We assumed that travel-associated mpox cases that contribute to the international 235 spread mostly reside in major metropolitan areas with international airport transportation hubs. 236 Hence, we considered a total of 39,114 mpox cases which occurred in 39 metropolitan areas with 237 major international airports in the top 12 countries affected by mpox (Tables S2 and S3) and 238 239 evaluate their risk of exportations to mainland China. Specifically, we obtained the time series of mpox incidence at the national level from Global.health(48). We then decomposed the national-240 level time series into metropolitan-level proportional to the relative outbreak size of a 241 metropolitan area with respect to its national total. For each mpox infection at the source location 242 *i*, we assume that the infected individual could only make international air travel during the 243 incubation period of τ days (i.e., prior to symptom onset), which we drew from a lognormal 244 distribution with an average of 8.94 days and standard deviation of 4.19 (Table S4). For each 245 case, we assumed there is a delay of σ days between symptom onset and the date of reporting, 246 drawing from a zero-inflated negative binomial distribution with an average of 6.48 days and a 247 standard deviation of 28.2 days (Supplement, section 4, Fig.S1). Consequently, if a mpox case is 248 reported on date t, this infected individual could potentially travel internationally between date 249 250 $t - \sigma$ and date $t - \sigma - \tau$, i.e., during his/her incubation period.

251

We then estimated the international air travel probability using the origin-destination air-252 travel data provided by Official Aviation Guide (OAG). The pandemic greatly influenced global 253 air travel. We considered a pre-pandemic (upper-bound) scenario using the air-travel data of year 254 2019 and a peri-pandemic (lower-bound) scenario using the air-travel data of year 2022. For each 255 air-travel scenario, if we denote the total air-travel volume at month m from location i to location 256 *j* as Φ_{ij}^m (provided by OAG), the per-capita rate of international air travel ϕ_{ij} can be expressed as 257 $\phi_{ij} = \frac{\Phi_{ij}^m}{N_i D_m}$, where N_i is the total population in location *i* and D_m is the number of days in month 258 m. We then iterated through all mpox cases and simulated each of their potential air-travel 259 trajectory during their incubation period τ : starting from the beginning of the incubation period 260 $t - \sigma - \tau$, for each day forward t' till the end of the incubation period $t - \sigma$, whether the 261 individual would travel on date t' is simulated as a Bernoulli process with the probability of travel 262 $p_i(t')$ from location *i* is given by $p_i = \sum_i \phi_{ii}(t')$. Given that the individual would travel on t', 263 then the destination *i* of the international travel would be decided based on a generalized 264 Bernoulli distribution with the conditional probability of traveling to a specific location *j* given by 265 $\frac{\phi_{ij}(tr)}{\sum_i \phi_{ij}(tr)}$ and the simulation for this infected individual ends. The simulation of the infected 266 individual would also end if by the end of his/her incubation period $t - \sigma$, the infected individual 267 does not travel, and this individual would remain as a local mpox case in location i. Once we 268 iterate through all mpox infections globally, we could sum up the cumulative number of mpox 269 importations from location i to location j up to time point t, denoted as $m_{ii}(t)$. We repeated the 270 entire simulation for a total of 200 times and obtained the distribution of $m_{ii}(t)$, denoted as 271 $P(m_{ij}(t))$ to capture the stochastic nature of the modelled process. We could estimate the mean 272 and 95% confidence interval (0.025 and 0.975 quantiles) of $m_{ij}(t)$ based on $P(m_{ij}(t))$. To 273 274 ensure the validity of our model, we performed a validation analysis of the mpox importations among countries where consecutive reports of mpox cases with international travel history were 275 276 available, with abovementioned pre-pandemic and peri-pandemic air-travel volume setting the upper bound and lower bound of the importation risks, respectively (Fig.S2). 277 278

279 Effectiveness of border screening against travel-associated mpox cases.

To quantify the effectiveness of border screening policies, we first considered a scenario 280 (denoted as Scenario 1 hereafter) that is in compliance with mainland China's current pandemic 281 quarantine policy for border entry: according to the recently published (July 1, 2022) guidelines to 282 mpox prevention and control by mainland China's National Health Commission, all international 283 travelers entering mainland China, especially for those who had travel history to regions with an 284 on-going mpox epidemic within 21 days of border entry, should be screened for mpox during 285 their mandatory quarantine as a part of mainland China's pandemic response(49). During the 286 quarantine, individuals are also screened for mpox related symptoms including fever and rash. 287 Symptomatic individuals with travel history from outbreak countries, close contact with 288 confirmed cases, or contact with infected animals would be defined as suspected cases (Table S5). 289 Once detected, they would be reported to the local CDC and will be transferred to designated 290 hospitals for a 21-day medical observation, and PCR test for lesion samples/swabs/blood will be 291 292 conducted. Considering the variation of pandemic mandatory quarantine durations (ranging from 7-21 days) as well as the uncertainty on the proportion of people with mpox infections complying 293 with self-reporting, we used a mathematical model to evaluate the proportion of imported mpox 294 infections detected post entry screening (Supplement, section 7). We also considered another 295 hypothetical scenario (denoted as Scenario 2 hereafter) of plausible mpox entry screening in the 296 absence of mainland China's pandemic quarantine policy for international travelers (a pre-297 298 pandemic scenario). In this scenario, international travelers with a self-reported mpox epidemiological link needed to undergo medical observation for mpox-related symptoms (e.g., 299 fever, rash, lymphadenopathy) during which they abstain from sexual activity, in addition to other 300 precautionary measures (29). Upon symptom onset, a suspected mpox case needs to self-isolate 301 and seek testing. We also evaluated the effectiveness of this travel screening policy (Supplement, 302 section 7). 303

304

305 Local outbreak probability.

Following Hartfield et al.'s analytical solution of outbreak probability as a function of the basic 306 reproduction number R_0 and overdispersion parameter k(30) (Supplement, section 8), we 307 explored the range of mpox outbreak probability with one initial infector introduced into the high-308 risk population in mainland China, with R_0 ranging from 1.1 to 2.0 and dispersion parameter k 309 ranging from 0.1 to 1.2 (Fig.4a). Our best guess for R_0 for the 2022 mpox outbreak is 1.8, 310 according to a recent study conducted by Kwok et al(44), and we consider a plausible dispersion 311 parameter k of 0.88 through fitting the negative binomial distribution for the number of sexual 312 partners among MSM in China(31, 32) (Fig.S3). For $R_0 = 1.8$, and k = 0.88, we explored how 313 the outbreak probability would change with the number of imported mpox cases missed by the 314 315 border screening process (Fig.4b). To understand the effect of emergency vaccination on preventing the outbreak probability, we used R_t to stand for the protection provided by 316 emergency vaccination. The relationship can be illustrated as $R_t = R_0 * S$, in which S stands for 317 the proportion of population susceptible to mpox. According to the US emergency vaccination of 318 mpox as well as the vaccine effectiveness(50, 51), we assumed 20% high risk population get 319 effectively vaccinated, hence the $R_t = 1.46$. 320

321 322

323

All analysis was done in R (version 4.1.1).

324 Acknowledgments

We would like to thank our team members (Yan Wang, Lan Yi, Jiayi Dong, Qianhui Wu, and Jun Cai) for communications on this study. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US National Institutes of

Health.

329

Author Contributions

- H.Yu and K.Sun conceived, designed, and supervised the study. X.Deng, Y.Tian, and J.Zou
- collected the data. X.Deng and K.Sun contributed to the methodology, designed the model.
- X.Deng and Y.Tian analyzed the model output. X.Deng, Y.Tian, K.Sun, and H.Yu interpreted the
- results. X.Deng and Y.Tian prepared the figures and tables. X.Deng and Y.Tian wrote the first
- draft of the manuscript. K.Sun, J.Yang and H.Yu critically revised the content. All authors
- approved the final manuscript as submitted and agree to be accountable for all aspects of thework.
- 338

Funding

- This work was supported by the Key Program of the National Natural Science Foundation of China under Grant 82130093.
- 342

343 Conflicts of Interest

- 344 H.Yu received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC
- 345 Changjiang Pharmaceutical Company, Shanghai Roche Pharmaceutical Company, and
- 346 SINOVAC Biotech Ltd. None of these are related to this study.
- 347

348 Data Availability

- The data that support the findings of this study are available from the corresponding author, upon reasonable request.
- 351

352 Supplementary Materials

- Fig. S1. Distribution of the interval from onset to report. (a) The probability density function. (b)
- The cumulative distribution function.
- Fig. S2. Validation of the importing risk estimation for 24 countries reporting importation cases more than three times.
- Fig. S3. Distribution of the number of sexual partners within 1 year among MSM community in mainland China.
- Fig. S4. Correlation between the confirmed mpox cases number and active MSM population size
- ³⁶⁰ of 31 provinces in mainland China.
- Table S1. Summary of epidemiological and clinical features.
- Table S2. Summary of case number and population of each metropolitan areas among top 12 countries affected by mpox.
- Table S3. Summary of international airports for each metropolitan area.
- Table S4. Fitting information for duration of rash.
- Table S5. Case Definitions of mpox in mainland China.
- Table S6. Summary of diagnostic accuracy of confirmation test.
- Table S7. R^2 for different regression combination.
- Table S8. Country/region ISO Alpha-3 code and the according UN name.
- 370

371	References	
372	1.	J. G. Breman et al., Human monkeypox, 1970-79. Bulletin of the World Health
373		Organization 58, 165-182 (1980).
374	2.	P. Venkatesan, Global monkeypox outbreak. Lancet Infect Dis 22, 950 (2022).
375	3.	WHO. (2022), vol. 2022.
376	4.	D. B. Di Giulio, P. B. Eckburg, Human monkeypox: an emerging zoonosis. Lancet Infect
377		Dis 4, 15-25 (2004).
378	5.	E. M. Bunge <i>et al.</i> , The changing epidemiology of human monkeypox-A potential threat?
379		A systematic review. PLoS Negl Trop Dis 16, e0010141 (2022).
380	6.	Centers for Disease and Prevention, Update: multistate outbreak of monkeypoxIllinois,
381		Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR. Morbidity and mortality
382		weekly report 52 , 642-646 (2003).
383	7.	G. D. Huhn et al., Clinical characteristics of human monkeypox, and risk factors for
384		severe disease. Clin Infect Dis 41, 1742-1751 (2005).
385	8.	V. Costello et al., Imported Monkeypox from International Traveler, Maryland, USA,
386		2021. Emerg Infect Dis 28, 1002-1005 (2022).
387	9.	F. S. Minhaj et al., Monkeypox Outbreak - Nine States, May 2022. MMWR. Morbidity
388		and mortality weekly report 71 , 764-769 (2022).
389	10.	A. Vaughan et al., Two cases of monkeypox imported to the United Kingdom, September
390		2018. Euro Surveill 23, (2018).
391	11.	N. Erez et al., Diagnosis of Imported Monkeypox, Israel, 2018. Emerg Infect Dis 25, 980-
392		983 (2019).
393	12.	S. E. F. Yong et al., Imported Monkeypox, Singapore. Emerg Infect Dis 26, 1826-1830
394		(2020).
395	13.	WHO, "Multi-country outbreak of monkeypox, External situation report #6 - 21
396		September 2022," (2022).
397	14.	L. Osadebe et al., Enhancing case definitions for surveillance of human monkeypox in the
398		Democratic Republic of Congo. PLoS Negl Trop Dis 11, e0005857 (2017).
399	15.	M. Perez Duque et al., Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May
400		2022. Euro Surveill 27 , (2022).
401	16.	E. R. Whitehouse <i>et al.</i> , Clinical and Epidemiological Findings from Enhanced
402		Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During
403	. –	2011-2015. The Journal of infectious diseases 223 , 1870-1878 (2021).
404	17.	A. Yinka-Ogunleye <i>et al.</i> , Outbreak of human monkeypox in Nigeria in 2017-18: a
405	10	clinical and epidemiological report. Lancet Infect Dis 19, 872-879 (2019).
406	18.	N. L. Bragazzi <i>et al.</i> , Epidemiological trends and clinical features of the ongoing
407		monkeypox epidemic: A preliminary pooled data analysis and literature review. <i>Journal of</i>
408	10	medical virology, (2022).
409	19. 20	WHO. (2023), vol. 2023.
410	20.	L. T. Allan-Blitz <i>et al.</i> , A Position Statement on Mpox as a Sexually Transmitted Disease.
411	21	<i>Clin Infect Dis</i> , (2022).
412	21.	WHO. (2022), vol. 2022.
413	22.	WHO. (2023), vol. 2023.
414	23.	A. Endo, S. M. Jung, F. Miura, Mpox emergence in Japan: ongoing risk of establishment
415 116	24.	in Asia. <i>Lancet</i> 401 , 1923-1924 (2023). L. a. W. Ministry of Health. (2023), vol. 2023.
416 417	24. 25.	L. a. w. Ministry of Health. (2023), vol. 2025. K. Yoon-mi. (2023), vol. 2023.
+17 418	23. 26.	WHO. (2023), vol. 2023.
+18 419	20. 27.	E. Jimenez, P. Suau-Sanchez, Reinterpreting the role of primary and secondary airports in
420	27.	low-cost carrier expansion in Europe. J Transp Geogr 88, 102847 (2020).

- 421 28. The Central People's Government of the People's Republic of China. (2022), vol. 2022.
- 422 29. ECDC, "Considerations for contact tracing during the monkeypox outbreak in Europe,
 423 2022," (2022).
- M. Hartfield, S. Alizon, Introducing the outbreak threshold in epidemiology. *PLoS Pathog*9, e1003277 (2013).
- L. Zhang, E. P. Chow, D. P. Wilson, Distributions and trends in sexual behaviors and HIV
 incidence among men who have sex with men in China. *BMC Public Health* 12, 546
 (2012).
- L. Zhang, E. P. Fung Chow, D. P. Wilson, Men who have sex with men in China have
 relatively low numbers of sexual partners. *Infectious disease reports* 3, e10 (2011).
- J. O. Lloyd-Smith, Vacated niches, competitive release and the community ecology of
 pathogen eradication. *Philos Trans R Soc Lond B Biol Sci* 368, 20120150 (2013).
- 433 34. Ministerio de Sanidad. (2022), vol. 2022.
- 434 35. Robert Koch-Institut. (2022), vol. 2022.
- 435 36. C. R. S. Madarang. (2022), vol. 2022.
- 436 37. Bernama. (2022), vol. 2022.
- 437 38. B. PULIPAKA. (2022), vol. 2022.
- 438 39. N. S. Ali. (2022), vol. 2022.
- 439 40. K. Arin. (2022), vol. 2022.
- 440 41. B. Y. tế. (2022), vol. 2022.
- 41 42. H. Zhao *et al.*, The First Imported Case of Monkeypox in the Mainland of China 442 Chongqing Municipality, China, September 16, 2022. *China CDC Wkly* 4, 853-854 (2022).
- 43. A. Endo *et al.*, Heavy-tailed sexual contact networks and monkeypox epidemiology in the 445 global outbreak, 2022. *Science* **378**, 90-94 (2022).
- 44. K. O. Kwok, W. I. Wei, A. Tang, S. Y. Shan Wong, J. W. Tang, Estimation of local
 transmissibility in the early phase of monkeypox epidemic in 2022. *Clin Microbiol Infect*,
 (2022).
- 45. M. Hu, C. Xu, J. Wang, Spatiotemporal Analysis of Men Who Have Sex With Men in
 450 Mainland China: Social App Capture-Recapture Method. *JMIR Mhealth Uhealth* 8,
 451 e14800 (2020).
- 46. J. A. Grey *et al.*, Estimating the Population Sizes of Men Who Have Sex With Men in US
 States and Counties Using Data From the American Community Survey. *JMIR Public Health Surveill* 2, e14 (2016).
- 455 47. WHO, "Multi-country outbreak of mpox," (2023).
- 48. M. U. G. Kraemer *et al.*, Tracking the 2022 monkeypox outbreak with epidemiological 457 data in real-time. *Lancet Infect Dis* **22**, 941-942 (2022).
- 458 49. National Health Commission of the People's Republic of China. (2022), vol. 2022.
- 459 50. CDC. (2023), vol. 2023.
- 460 51. CDC. (2023), vol. 2023.
- 461 462




Fig. 1. Spatial distribution of mpox cases. Spatial distribution of confirmed mpox cases from January 1, 2022 to June 13, 2023. Shapes in color of ivory indicate that data in countries/regions is not available (NA).




Fig. 2. The air-travel volume and the expected number of mpox importations in China. (A) The expected cumulative number of mpox importations from May to September 2022 with air-traffic volume in 2019 and 2022. (B) The expected number of mpox case importation from other countries/regions with air-traffic volume in 2019 and 2022. In panel a, the inset indicates the monthly air-travel volume to mainland China from 2017 to 2022. In panel b, the three letter texts are ISO Alpha-3 codes, i.e., DEU denotes Germany, ESP denotes Spain, GBR denotes the UK, etc. Detailed ISO Aplha-3 codes can be seen in Table S8.




Fig. 3. Effectiveness of mpox border screening policies under two assumed scenarios. (A) Number of total detected mpox cases under Scenario 1 (corresponding to China's pandemic quarantine policy), with proportion of self-reported epidemiological links ranging from 10% to 100%, and days of quarantine ranging from 0 to 21. (B) Number of total detected mpox cases under Scenario 2 (a pre-pandemic scenario), with proportion of self-reported epidemiological links ranging from 10% to 100%, and days of medical observation ranging from 0 to 21. (C) Number of total detected mpox cases with 50% self-reported epidemiological links of quarantine or medical observation from 0 to 21. In panel c, the horizonal lines indicate the mean, with dark and light shades indicating 50% CI, and 95% confidence interval.




Fig. 4. Estimated outbreak probability. (a) the outbreak probability of one mpox case introduced into the MSM community in mainland China, with R0 ranges from 1.1 to 2, and dispersion parameter k ranges from 0.1 to 1.2. In panel a, the dashed lines and dot refer to $R_0=1.8$ and k=0.88, a plausible guess of mpox transmissibility in mainland China. (b) the outbreak probability as a function of the number of seeding infectors ranges from 1 to 10, with $R_0=1.8$ and k=0.88.